Rx Drug Ads Should Not Characterize Probability Of Risk As Insignificant, FDA Emphasizes

 
• By Brenda Sandburg

Agency’s final guidance on presenting quantitative efficacy and risk information in direct-to-consumer advertisements includes an additional example, which specifies risk should not be characterized in a way that suggests it is not important.

Quantifying benefits and risks
FDA guidance advises drug manufacturers how to present quantitative efficacy and risk information in direct-to-consumer promotions • Source: Shutterstock

More from Marketing & Advertising

More from Compliance